Grifols Future Growth

Future criteria checks 4/6

Grifols is forecast to grow earnings and revenue by 28.8% and 5.9% per annum respectively. EPS is expected to grow by 31.5% per annum. Return on equity is forecast to be 11.5% in 3 years.

Key information

28.8%

Earnings growth rate

31.5%

EPS growth rate

Biotechs earnings growth	30.9%
Revenue growth rate	5.9%
Future return on equity	11.5%
Analyst coverage	Good
Last updated	06 May 2024

Recent future growth updates

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Recent updates

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

May 18

Is Grifols (BME:GRF) Using Too Much Debt?

Apr 30

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Nov 18

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Oct 26

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Aug 18

Earnings and Revenue Growth Forecasts

BME:GRF - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8,033	822	873	1,207	7
12/31/2025	7,641	722	687	1,014	13
12/31/2024	7,097	468	530	856	14
12/31/2023	6,592	59	-87	208	N/A
9/30/2023	6,535	23	-217	119	N/A
6/30/2023	6,479	8	-505	-146	N/A
3/31/2023	6,358	47	-485	-107	N/A
12/31/2022	6,064	208	-386	-11	N/A
9/30/2022	5,549	149	-272	50	N/A
6/30/2022	5,207	66	-36	289	N/A
3/31/2022	5,016	112	137	454	N/A
12/31/2021	4,933	189	282	597	N/A
9/30/2021	5,044	361	400	727	N/A
6/30/2021	5,199	667	597	909	N/A
3/31/2021	5,231	562	847	1,183	N/A
12/31/2020	5,340	619	748	1,110	N/A
9/30/2020	5,392	687	663	1,081	N/A
6/30/2020	5,353	557	551	964	N/A
3/31/2020	5,235	697	425	842	N/A
12/31/2019	5,099	625	157	569	N/A
9/30/2019	4,961	552	309	668	N/A
6/30/2019	4,790	565	275	634	N/A
3/31/2019	4,620	568	147	477	N/A
12/31/2018	4,487	597	430	737	N/A
9/30/2018	4,332	699	365	680	N/A
6/30/2018	4,246	704	405	712	N/A
3/31/2018	4,279	672	473	789	N/A
12/31/2017	4,318	663	519	842	N/A
9/30/2017	4,348	571	N/A	751	N/A
6/30/2017	4,291	559	N/A	765	N/A
3/31/2017	4,153	554	N/A	640	N/A
12/31/2016	4,050	545	N/A	553	N/A
9/30/2016	4,014	537	N/A	683	N/A
6/30/2016	3,986	535	N/A	652	N/A
3/31/2016	3,985	529	N/A	767	N/A
12/31/2015	3,935	532	N/A	743	N/A
9/30/2015	3,789	533	N/A	755	N/A
6/30/2015	3,645	507	N/A	836	N/A
3/31/2015	3,466	478	N/A	888	N/A
12/31/2014	3,355	470	N/A	979	N/A
9/30/2014	3,133	417	N/A	882	N/A
6/30/2014	2,972	388	N/A	712	N/A
3/31/2014	2,856	376	N/A	625	N/A
12/31/2013	2,742	346	N/A	592	N/A
9/30/2013	2,708	326	N/A	525	N/A
6/30/2013	2,685	306	N/A	573	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRF's forecast earnings growth (28.8% per year) is above the savings rate (1.5%).

Earnings vs Market: GRF's earnings (28.8% per year) are forecast to grow faster than the Spanish market (9.2% per year).

High Growth Earnings: GRF's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GRF's revenue (5.9% per year) is forecast to grow faster than the Spanish market (3.9% per year).

High Growth Revenue: GRF's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GRF's Return on Equity is forecast to be low in 3 years time (11.5%).

Grifols Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 7.1% to €17.40

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Recent updates

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Consensus EPS estimates fall by 12%

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of Grifols, S.A. (BME:GRF)

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Consensus EPS estimates fall by 54%

Investor sentiment improves as stock rises 19%

Is Grifols (BME:GRF) Using Too Much Debt?

Consensus EPS estimates increase by 31%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues exceed analyst expectations

Consensus EPS estimates fall by 12%

Now 21% undervalued

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Now 20% undervalued

Grifols (BME:GRF) Seems To Be Using A Lot Of Debt

Insufficient new directors

Price target decreased to €18.53

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued

Insufficient new directors

Grifols Announces Management Changes

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Second quarter 2022 earnings: Revenues exceed analyst expectations

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Now 21% undervalued after recent price drop

Now 21% undervalued

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts